Valuation: Cybin Inc.

Market Cap 620M 441M 386M 357M 328M 42.5B 630M 4.27B 1.67B 20.79B 1.65B 1.62B 71.64B P/E 2027 *
-2.63x
P/E 2028 * -3.12x
Enterprise Value 181M 129M 113M 104M 96M 12.42B 184M 1.25B 489M 6.08B 484M 473M 20.94B EV / Sales 2027 *
-
EV / Sales 2028 * 4.71x
Free-Float
97.25%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Cybin Inc.

Manager TitleAgeSince
Chief Operating Officer 37 2016-10-12
Chief Executive Officer 51 2026-04-19
Director of Finance/CFO 56 2020-11-04
Director TitleAgeSince
Chairman 51 2020-11-04
Director/Board Member 37 2016-10-12
Director/Board Member 65 2020-11-04
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%-4.10% - - 449M
+0.21%-0.79%+53.17%+57.39% 53.83B
+5.37%+3.31%+50.39%+83.65% 52.1B
-1.20%-1.94%+4.35%+402.68% 23.48B
+0.74%+2.32%-16.23%-14.44% 23.13B
+0.21%+0.37%+36.93%-5.80% 19.36B
-1.18%-2.97%+30.12%-33.30% 17.56B
-1.67%-6.00%+163.95%+284.69% 15.2B
-0.83%+0.32%+32.36%+570.87% 14.83B
-0.70%-0.91%+24.87%+179.47% 14.06B
Average -0.06%-0.80%+42.21%+169.47% 25.95B
Weighted average by Cap. +0.92%-1.02%+41.87%+133.53%

Financials

2027 *2028 *
Net sales - 3.65M 2.6M 2.28M 2.1M 1.93M 250M 3.71M 25.15M 9.86M 122M 9.75M 9.54M 422M
Net income -252M -179M -157M -145M -134M -17.3B -256M -1.74B -681M -8.47B -674M -659M -29.17B -276M -196M -172M -159M -146M -18.92B -280M -1.9B -745M -9.26B -737M -721M -31.9B
Net Debt -438M -312M -273M -253M -232M -30.07B -446M -3.02B -1.18B -14.71B -1.17B -1.15B -50.7B -602M -428M -376M -347M -319M -41.32B -612M -4.15B -1.63B -20.22B -1.61B -1.57B -69.65B
Logo Cybin Inc.
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.996CAD
Average target price
52.87CAD
Spread / Average Target
+428.87%

Quarterly revenue - Rate of surprise